Zalifrelimab
Zalifrelimab Basic information
- Product Name:
- Zalifrelimab
- Synonyms:
-
- Zalifrelimab
- Research Grade Zalifrelimab (DHD17202)
- Research Grade Zalifrelimab
- Zalifrelimab (anti-CTLA-4)
- CAS:
- 2148321-69-9
- MW:
- 0
- Mol File:
- Mol File
Zalifrelimab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Zalifrelimab Usage And Synthesis
Uses
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling[1].
in vivo
Zalifrelimab (AGEN1884; 10 mg/kg; i.v.; on days 1 and 29) is well-tolerated in non-human primates and enhances vaccine-mediated antigen-specific immunity[2].
| Animal Model: | Cynomolgus macaques (Macaca fascicularis)[2] |
| Dosage: | 10 mg/kg |
| Administration: | i.v.; on days 1 and 29 |
| Result: | Enhanced antigen-specific immune responses in combination with reporter vaccines in vivo. |
References
[1] David M O'Malley, et al. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. J Clin Oncol. 2022 Mar 1;40(7):762-771. DOI:10.1200/JCO.21.02067
[2] Randi B Gombos, et al. Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. PLoS One. 2018 Apr 4;13(4):e0191926. DOI:10.1371/journal.pone.0191926
ZalifrelimabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com